

RESEARCH

Open Access



Ultrasound-based radiomics for predicting different pathological subtypes of epithelial ovarian cancer before surgery

Zhi-Ping Tang^{1†}, Zhen Ma^{1,2†}, Yun He¹, Ruo-Chuan Liu¹, Bin-Bin Jin¹, Dong-Yue Wen¹, Rong Wen¹, Hai-Hui Yin¹, Cheng-Cheng Qiu¹, Rui-Zhi Gao¹, Yan Ma^{1*†} and Hong Yang^{1*†}

Abstract

Objective: To evaluate the value of ultrasound-based radiomics in the preoperative prediction of type I and type II epithelial ovarian cancer.

Methods: A total of 154 patients with epithelial ovarian cancer were enrolled retrospectively. There were 102 unilateral lesions and 52 bilateral lesions among a total of 206 lesions. The data for the 206 lesions were randomly divided into a training set (53 type I + 71 type II) and a test set (36 type I + 46 type II) by random sampling. ITK-SNAP software was used to manually outline the boundary of the tumor, that is, the region of interest, and 4976 features were extracted. The quantitative expression values of the radiomics features were normalized by the Z-score method, and the 7 features with the most differences were screened by using the Lasso regression tenfold cross-validation method. The radiomics model was established by logistic regression. The training set was used to construct the model, and the test set was used to evaluate the predictive efficiency of the model. On the basis of multifactor logistic regression analysis, combined with the radiomics score of each patient, a comprehensive prediction model was established, the nomogram was drawn, and the prediction effect was evaluated by analyzing the area under the receiver operating characteristic curve (AUC), calibration curve and decision curve.

Results: The AUCs of the training set and test set in the radiomics model and comprehensive model were 0.817 and 0.731 and 0.982 and 0.886, respectively. The calibration curve showed that the two models were in good agreement. The clinical decision curve showed that both methods had good clinical practicability.

Conclusion: The radiomics model based on ultrasound images has a good predictive effect for the preoperative differential diagnosis of type I and type II epithelial ovarian cancer. The comprehensive model has higher prediction efficiency.

Keywords: Epithelial ovarian cancer, Ovarian neoplasms, Histological classification, Ultrasonic examination, Radiomics

Introduction

Ovarian cancer is the deadliest cancer of the female reproductive system [1, 2]. Approximately 13,940 women in the United States died of the disease in 2020 [3]. According to the female reproductive organ tumor classification system published by the World Health Organization in 2014 [4], type I epithelial ovarian cancer includes

[†]Zhi-Ping Tang and Zhen Ma contributed equally as co-first authors

[†]Hong Yang and Yan Ma contributed equally as co-corresponding authors of this paper

*Correspondence: luoma628@163.com; yanghong@gxmu.edu.cn

¹Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Full list of author information is available at the end of the article



low-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma and malignant Brenner tumor. Type II epithelial ovarian cancer includes high-grade serous carcinoma, carcinosarcoma and undifferentiated carcinoma. Epithelial ovarian cancer has the highest fatality rate among malignant tumors of the female reproductive system, and different types are closely related to prognosis. The overall prognosis of type I is good, while that of type II is poor [5]. Therefore, it is of great clinical significance to improve the accuracy of preoperative diagnosis [3, 6]. Early identification of epithelial ovarian cancer subtypes is of great importance [7–9].

Traditional imaging is the main means of detecting ovarian tumors [7], but this method largely depends on the doctor's personal experience [10], and some tumor-specific imaging features cannot be recognized by the naked eye, resulting in clinical diagnosis inefficiencies. Radiomics is more objective than traditional imaging methods. It extracts high-throughput image features from traditional medical images to quantitatively analyze diseases and provides new insights into the clinical diagnosis and treatment of ovarian tumors [11, 12].

Radiomics, first proposed by Lambin et al. in 2012 [11], has developed rapidly in recent years [13]. It provides a noninvasive method for diagnosing and predicting diseases. Gulshan V et al. diagnosed diabetic retinopathy by analyzing 128,175 retinal images [14–16]. Yin et al.


established a radiomics model using MR images and effectively identified chordomas, giant cell tumors and metastatic tumors before operation [17]. Peng et al. developed a radiomics model for the preoperative recognition of HCC and non-HCC using ultrasound images [18]. It is widely regarded as a step in the development of radiomics for personalized cancer management [13].

At present, there is a lack of ultrasound-based radiomics methods for distinguishing different subtypes of epithelial ovarian cancer before surgery [19]; therefore, the purpose of this study was to establish and verify an objective ultrasound-based radiomics evaluation model for the preoperative prediction of type I and type II epithelial ovarian cancer. Accurate prediction of tissue classification of epithelial ovarian cancer before operation can provide more accurate treatment plan for clinic and better decision-making for patients.

Materials and methods

Research population

The Ethics Committee of the First Affiliated Hospital of Guangxi Medical University approved this retrospective study (approval number: NO.2022 -KY-E-(056). Informed consent was waived. Patients with epithelial ovarian cancer diagnosed by pathology after surgery at the First Affiliated Hospital of Guangxi Medical University from January 2017 to September 2021 were enrolled (Fig. 1). The inclusion criteria were as follows: (1) primary



epithelial ovarian cancer; (2) lesions confirmed by operation and pathology; (3) transvaginal ultrasound examination of ovaries within 14 days before operation; and (4) clear ultrasound images. The exclusion criteria were as follows: (1) preoperative anticancer therapy; (2) poor image quality; and (3) incomplete clinical data. Finally, a total of 154 patients were included, with an average age of 50.15 ± 10.80 years and a range of 21–76 years.

Instruments and methods of ultrasonic examination

Using a GE Volusion E10 and E8 ultrasonic diagnostic apparatus, the transvaginal probe type was RIC5-9 Mel D, and the frequency was 5–9 MHz. Transvaginal ultrasonography was used to scan ovarian tumors from

multiple sections and angles to understand the overall information. Then, we carefully scanned and observed the size, shape and echo of the tumor, selected the largest section of the tumor with the clearest imaging, and saved the image in medical digital imaging and communication format to maximize the preservation of the image information.

Image segmentation and feature extraction

The image was imported into ITK-SNAP software (version 3.8) to manually draw the tumor boundary and determine the tumor area of interest (ROI) (Fig. 2). The ultrasonographic manifestations of ovarian cancer can be divided into two types, one is solid, the other is mixed.




Fig. 2 Schematic outline of the region of interest (ROI) of epithelial ovarian cancer. **A, D, G** The biggest section of the ultrasound image of epithelial ovarian cancer. **B, E, H** The red line delineates the ROI along the edge of the lesion. **C, F, I** Schematic of the cut image. **A, B, C** show a case of ovarian clear cell carcinoma. **D, E, F** show a case of low-grade serous carcinoma of the ovary. **G, H, I** show a case of high-grade serous carcinoma of the ovary

Our standard for drawing ROI is to draw along the edge of the tumor, if it is a solid mass, we will outline the whole solid part, if it is a mixed mass, we will outline the whole edge of the mass, including the solid part and the liquid part. All tumor areas of interest were delineated under the supervision of an ultrasound doctor with 10 years of ultrasound diagnosis experience and another ultrasound doctor with 15 years of experience in ultrasound diagnosis. Neither ultrasound doctor knew the pathology results. Also, 50 images were randomly selected from all the images and drawn independently by two doctors to evaluate consistency between different observers. 171 features were selected from 50 images for repeated verification. Figure 3 showed the repeatability of standardized imaging features through histograms. Using the lower bound of 95% confidence interval, the intra-class correlation coefficient of absolute consistency of features (difference < 0.50; moderate: 0.50–0.75; advantages: 0.75–0.90; excellent > 0.90). The bar chart shows that the features extracted by the ROI sketched by the two doctors are highly repetitive.

IntelligenceFoundry software (GE Healthcare, version 1.3) was used to analyze and extract radiomics features. Feature types included first-order features (energy, mean, skewness, kurtosis, etc.), shape features (minor axis length, major axis length, extension, etc.), wavelet features and texture features [gray co-occurrence matrix (GLCM) features, gray run length matrix (GLRLM) features, etc.]. A total of 4976 high-throughput features were extracted in this study. The feature parameters extracted by the Intelligence Foundry software were based on the algorithm provided by the pyRadiomics package, which calculates radiomics features according to the feature




Fig. 3 showed the repeatability of standardized imaging features through histograms. Using the lower bound of 95% confidence interval, the intra-class correlation coefficient of absolute consistency of features (difference < 0.50; moderate: 0.50–0.75; advantages: 0.75–0.90; excellent > 0.90). Figure 3 showed that the features extracted by the ROI sketched by the two doctors were highly repetitive

definition described in the Image Biomarker Standardization Initiative (IBSI) version 2016 [20, 21]. The median was used to fill in the missing extracted eigenvalues and replace the outliers. The Z-score normalization method was used to convert different data into the same order of magnitude, and the calculation formula was as follows: $y = (x - \mu) / \sigma$, where μ is the mean and σ is the standard deviation.

Data preprocessing

Patients with epithelial ovarian cancer were marked with different labels according to their histological types. Type I epithelial ovarian cancer was labeled "0", and type II epithelial ovarian cancer was labeled "1". Then, using the method of stratified sampling, patients with two histological types of epithelial ovarian cancer were randomly divided into two groups according to a 6:4 (training set:test set) ratio. The training set was used to build the model, and the test set was used to verify the effectiveness of the model.

Ultrasonic parameters



In this study, all patients were diagnosed with GEVolution ultrasound and were examined under the transvaginal probe. We collected the important ultrasonic parameters of all the pictures in this study, including gain, mechanical index, depth, angle. After analysis, we found that these important parameters were not statistically significant in the two types of ovarian cancer ($P > 0.05$). (Table 1).

Feature selection

In this study, a total of 4976 features were extracted from ultrasound images. To increase the comparability of quantitative radiomic features, we performed Z-score normalization for quantitative features in training and test sets. In order to reduce the influence of high-dimensional features on the model, we use lasso regression method to downscale features, and select the optimal feature subset through ten-fold cross-validation. (Figs. 4 and 5). Finally, seven features with the most differences were obtained in this study. The scatter plot showed significant differences between type I and type II epithelial ovarian cancer (Fig. 6). According to the heatmap, the correlation of the

Table 1 The ultrasound parameter of the type I and the type II are shown in

Variable	Type I (n = 89)	Type II (n = 117)	P
Gain (dB)	6.00 (2.00–10.00)	5.00 (2.00–10.00)	0.248
Mechanical index	0.80 (0.70–1.00)	0.80 (0.70–1.00)	0.820
Depth (cm)	8.00 (7.70–10.10)	8.00 (7.70–10.10)	0.387
Angle (°)	179.00 (178.00–180.00)	179.00 (178.00–180.00)	0.255




seven selected features was small, and the influence of multicollinearity was eliminated (Fig. 7).

Image group model and evaluation

The seven radiomics features selected were introduced into the classifier to establish a model for evaluating two different histopathological types of epithelial ovarian cancer. We used six machine learning methods (random forest, linear judgment analysis, support vector machine, logistic regression, naive Bayesian, limit gradient lifting algorithm) to construct the model learning method (Fig. 8). Finally, the method with the highest AUC value was selected, and the optimal radiomics model (logistic regression model) was established (Fig. 9). Each feature was multiplied by its regression coefficient and summed. The result was the radiomics score of each patient.

Clinical parameter processing

Basic information (age, BMI), menopausal status, maximum tumor diameter, serum tumor marker levels, ascites and histopathological classification were collected. Serum tumor markers included carcinoembryonic antigen, glycosyl antigen 125, glycosyl antigen 153, glycosyl antigen 199, squamous cell carcinoma-associated antigen, serum human chorionic gonadotropin, human epididymal



epithelial secretory protein 4, alpha-fetoprotein, the Premenopausal ROMA index and the Postmenopausal ROMA index. The above data were detected within two weeks before the operation. The markers selected by the LASSO method were analyzed by multivariate analysis, and the markers with $P < 0.05$ were selected to establish the prediction model.

Comprehensive model establishment

The selected features were used to construct a radiomics model by logistic regression, and a comprehensive prediction model was obtained by combining the radiomics score with clinical parameters (Fig. 9). The comprehensive prediction model is displayed in the form of nomogram (Fig. 10). Finally, the test group evaluation model was used, and the evaluation indicators were AUC, accuracy, sensitivity and specificity. Calibration curves were used to evaluate the consistency of the model (Fig. 11), and decision curve analysis (DCA) was used to assess the clinical significance of the model by quantifying the net benefits under different threshold probabilities (Fig. 12).

Statistical analysis

R software (version 3.6.0) and SPSS software (version 22.0) were used for statistical analysis. For the measurement data of normal distribution, the t test of complete random design was used to compare the two samples, and the analysis of variance was used to compare several independent samples. The variables were summed as the mean \pm standard deviation (*SD*). For the skewness distribution measurement data, the rank sum test was used for the progressive nonparametric test, and the variables

were summed as $M (Q1 \sim Q3)$. The counting data were tested by the chi-square test, and the variables are presented as percentages.

Results

Clinical data

At the end of this study, 154 patients with epithelial ovarian cancer were enrolled, with an average age of 50.15 ± 10.80 years, ranging from 21 to 76 years old. Seventy-three patients (mean age 48.55 ± 12.17 years; range 24–76 years) were confirmed to have type I epithelial ovarian cancer by postoperative pathology; 33 of these patients had low-grade serous carcinoma, 20 had clear cell carcinoma, 9 had endometrioid carcinoma, and 11 had mucinous carcinoma. Eighty-one patients (mean age 51.36 ± 9.50 years; range 21–74 years) were confirmed to have type II epithelial ovarian cancer by postoperative pathology; 80 of these patients had high-grade serous carcinoma, and 1 of these patients had undifferentiated carcinoma. Among the 154 patients, 102 had unilateral lesions, and 52 had bilateral lesions; of the 206 total lesions, 89 were type I epithelial ovarian cancer, and 117 were type II epithelial ovarian cancer.

Radiomics data

Among the 154 patients with epithelial ovarian cancer, the training set included 93 patients, with 62 unilateral lesions and 31 bilateral lesions. The total number of lesions in the training set was 124, and the number of type I and type II epithelial ovarian cancer lesions was 53 and 71, respectively. The test set included 61 patients, with 40 unilateral lesions and 21 bilateral lesions. The




Fig. 7 The redder the color, the higher the correlation; the bluer the color, the lower the correlation. According to the heatmap, the correlation of the seven selected features is small and the influence of multicollinearity is eliminated

total number of lesions in the test set was 82, and the number of type I and type II epithelial ovarian cancer lesions was 36 and 46, respectively. The clinical parameters of the training set and the test set are shown in Table 2. There was no significant difference in the distribution of the clinicopathological features, including age, BMI, maximum tumor diameter, serum tumor marker levels, HE4, ROMA index, pathological subtypes, menopausal status and ascites, between the two groups.

Radiomics feature extraction



A total of 4976 features were extracted and normalized. The features with differences were screened by Lasso regression tenfold cross-validation and minimum absolute shrinkage (Figs. 4, 5). Finally, 7 optimal features were obtained. The heatmap is shown in Fig. 7. The correlation between features is represented by color. The redder

the color is, the higher the correlation is. In contrast, the bluer the color is, the lower the correlation is. The heatmap shows that the correlation of the selected seven features is very small, eliminating the effect of multicollinearity. The scatter plot shows that the seven optimal features selected were quite different between type I and type II epithelial ovarian cancer (Fig. 6).

Model construction and evaluation



The radiomics model has a high overall classification performance in identifying epithelial ovarian cancer types I and II, with AUC values of 0.817 and 0.731 in the training set and test set, respectively (Fig. 9).

Combined with the results of multivariate logistic regression analysis (Table 3), a comprehensive predictive model was constructed by combining menopausal state,ascites, CA125, SCC, HE4, Premenopausal ROMA,



Postmenopausal ROMA and Radiomics score. The AUC values in the training set and test set were 0.982 and 0.886, respectively (Fig. 9). The difference in performance between the simple radiomics model and the complete nomogram is statistically significant ($P < 0.05$).

The nomogram based on the comprehensive prediction model is shown in Fig. 10, which quantifies the factors of each patient and can be used to predict type I and type II epithelial ovarian cancer more intuitively before operation. The calibration curve shows that the radiomics



model is in good agreement with the comprehensive model, as shown in Fig. 11. The decision analysis curve shows that both models have good clinical practicability, as shown in Fig. 12.

Discussion

The ultrasound images of 154 patients with epithelial ovarian cancer were included in this study. The quantitative expression values of imaging features were




Fig. 12 Decision curve analysis is used to assess the clinical significance of the model by quantifying the net benefits under different threshold probabilities. The blue curve represents the radiomics model, The red curve represents the comprehensive model. Both models have higher clinical benefit values

normalized with the Z-score method, and the 7 most different features were screened by using the Lasso regression tenfold cross-validation method. Then, six machine learning methods (random forest, linear judgment analysis, support vector machine, logistic regression, naive Bayesian, limit gradient lifting algorithm) were used to construct the model, and the method with the highest AUC value was selected to establish the logistic regression radiology model. The AUCs of the training group and test group were 0.817 and 0.731, respectively. In addition, combined with the clinical indexes of the patients, the data regarding serum tumor markers monitored two weeks before operation were collected and analyzed by multivariate logistic regression analysis. Finally, menopausal state, ascites, CA125, SCC, HE4 and Premenopausal and Postmenopausal ROMA were identified as independent factors. The above indexes were combined with the radiomics score to create a comprehensive prediction model, and the AUCs in the training group and test group were 0.982 and 0.886, respectively. The nomogram of this study quantifies the value of each factor of the patient and visually shows the efficiency of the comprehensive model in predicting two kinds of epithelial ovarian cancer. From the value of AUC, the efficacy of comprehensive prediction model is higher than radiomics model. After analysis, the following factors were obtained. Firstly, this study collected a lot of clinical indicators, including maximum tumor diameter, ascites, carcinoembryonic antigen, glycosyl antigen 125,

Table 2 The clinical parameters of the training set and the test set are shown in

Variable	Training set (n = 124)	Test set (n = 82)	P
Age(years)	50.00 (43.00–56.00)	52.50 (46.00–59.00)	0.114
BMI	22.69 (20.25–25.19)	22.03 (19.92–24.20)	0.161
Maximum diameter of tumor (mm)	80.00 (53.00–105.00)	94.50 (57.00–115.00)	0.124
CEA (ng/ml)	1.70 (0.90–2.60)	1.71 (1.12–2.89)	0.431
CA125 (IU/ml)	692.00 (164.50–1384.6)	561.70 (143.50–1296.5)	0.431
CA153 (IU/ml)	34.54 (15.50–72.20)	36.35 (16.36–95.05)	0.776
CA199 (IU/ml)	12.28 (4.32–108.44)	17.32 (4.24–73.34)	0.694
SCC (ng/L)	0.70 (0.50–1.10)	0.60 (0.50–1.20)	0.830
HCG (mIU/ml)	0.56 (0.10–1.88)	1.02 (0.10–2.14)	0.149
HE4	172.70 (76.10–498.50)	159.60 (73.20–519.90)	0.602
AFP(ng/ml)	2.34 (1.79–3.27)	2.43 (1.58–3.35)	0.983
pre ROMA	69.33 (19.41–96.68)	60.97 (18.34–97.53)	0.630
post ROMA	79.61 (46.90–99.96)	76.96 (45.97–99.84)	0.502
Menopausal.state #			0.993
NO	53 (42.75)	35 (42.68)	
YES	71 (57.25)	47 (57.32)	
Ascites #			0.309
NO	45 (36.29)	36 (43.90)	
YES	79 (63.71)	46 (56.10)	
Figo stage #			0.106
I-II	50 (40.32)	24 (29.27)	
III-IV	74 (59.68)	58 (70.73)	

The counting data

Pre ROMA, Premenopausal ROMA; Post ROMA, Postmenopausal ROMA

glycosyl antigen 153, glycosyl antigen 199, squamous cell carcinoma-associated antigen, serum human chorionic gonadotropin, human epididymal epithelial secretory protein 4, alpha-fetoprotein, the Premenopausal ROMA index and the Postmenopausal ROMA index. The two indexes of maximum tumor diameter, ascites came from ultrasonic testing. Therefore, these indexes are not only simple blood test indexes, but also comprehensive indexes of patients' basic information, blood biochemistry and ultrasonic examination. Ultrasound has certain advantages in daily work. Ultrasonic operation is convenient, simple and non-invasive. It can also monitor the size of the mass and the presence of ascites. Therefore, ultrasound is a common method to detect ovarian tumors in clinical work. At the same time, radiomics also provides a new evaluation method for clinic, which has a certain potential value. In this study, the clinical decision curve shows that both the imaging model and the joint model are located above the None line and the All line, indicating that both models are valuable in predicting

Table 3 The markers selected by the LASSO method are analyzed by multivariate analysis

Variable	Univariate		Multivariate	
	OR (95%CI)	P	OR (95%CI)	P
Age(years)	1.021 (0.986–1.057)	0.244	–	
Height(cm)	0.980 (0.907–1.059)	0.604	–	
Weight(kg)	0.999 (0.971–1.028)	0.955	–	
BMI	1.003 (0.933–1.077)	0.940	–	
Menopausal state	0.987 (0.976–0.999)	0.857	13.347 (2.108–84.522)	0.006
Maximum diameter of tumor (mm)	1.103 (0.938–1.298)	0.036		
Ascites	22.333 (8.599–58.007)	0.000	189.06 (17.679–2021.839)	0.000
CEA(ng/m)*	1.116 (0.761–1.636)	0.575	–	
CA125(IU/ml)*	3.621 (2.315–5.663)	0.000	10.357 (3.543–30.275)	0.000
CA153(IU/ml)*	1.976 (1.342–2.908)	0.001	–	
CA199(IU/ml)*	0.939 (0.782–1.128)	0.504	–	
SCC(ng/L)*	0.767 (0.4–1.468)	0.422	0.131 (0.032–0.528)	0.004
HCG(mIU/ml.)*	0.928 (0.796–1.081)	0.338	–	
HE4*	1.278 (0.954–1.711)	0.100	0.262 (0.097–0.709)	0.008
AFP(ng/ml)*	1.563 (0.868–2.814)	0.137	–	
Pre ROMA*	1.602 (1.089–2.358)	0.017	20.908 (2.6–168.14)	0.004
Post ROMA*	2.281 (1.163–4.474)	0.016	0.001 (0–0.097)	0.003

*For log

Pre ROMA, Premenopausal ROMA; Post ROMA, Postmenopausal ROMA

the classification of epithelial ovarian cancer, and the net return of the combined model is higher than that of the radiomics model. Because the progression of type I and type II epithelial ovarian cancer is different, it is of clinical significance to correctly predict the two types.

Radiomics, first proposed by Lambin et al. in 2012 [11], has developed rapidly in recent years [13]. It provides a noninvasive method for diagnosing and predicting diseases and is widely regarded as a step in the development of radiomics for personalized cancer management. At present, most studies are based on CT and MR images. Qian et al. retrospectively analyzed 65 patients with epithelial ovarian cancer using conventional MRI images to compare the differences between radiomics models and traditional models in identifying early and advanced epithelial ovarian cancer [22]. Zhu et al. performed a retrospective analysis of 101 patients with ovarian cancer based on CT images and established a model to distinguish epithelial ovarian cancer from nonepithelial ovarian cancer by radiology combined with a clinical model [23]. Compared with the above studies, the purpose of our study was more precise, specifically for the preoperative prediction of pathological subtypes of epithelial ovarian cancer, which may provide a new approach for the current accurate medical treatment. In addition, our study had more patients and features, including a total of 154 patients and extracting 4976 radiomic features.

Compared with CT and MRI, ultrasound has the advantages of being simple operate and providing real-time observation, and it plays an important role in the diagnosis and treatment of ovarian tumors [24–26]. Therefore, with the remarkable progress of computer technology, the attempt to apply artificial intelligence to clinical practice has become increasingly feasible, and there will certainly be important breakthroughs in the future [13, 27–30].

However, our research also has some limitations. First, all the ultrasound imaging data came from a single center, and the study was retrospective, so it was necessary to conduct a multicenter prospective study. Second, our study only included epithelial ovarian cancer, excluding benign, borderline, sex cord interstitial and germ cell tumors of the ovary. We will add data on other types of ovarian tumors in future studies to optimize the universality and clinical value of the model. In addition, We are also trying to use radiomics to distinguish benign and malignant ovarian tumors, hoping that it can provide us with new ideas in differential diagnosis.

Conclusions

In summary, we developed and validated a radiomics model based on ultrasound to distinguish different histopathological types of epithelial ovarian cancer. Thus, it provides clinicians with a new method for the

noninvasive preoperative identification of type I and type II epithelial ovarian cancer.

Acknowledgements

Not applicable.

Author contributions

ZPT, ZM, YH, RW, HHY, CCQ and BBJ made substantial contributions to the conception and design of the present study. ZPT, ZM, CCQ, RZG and YM assisted in the acquisition, analysis and interpretation of data. ZPT, RCL, RW and HHY were involved in drafting the manuscript and YM, YH and HY critically revising it for important intellectual content. All authors gave final approval for the version of the manuscript to be published. All authors read and approved the final manuscript.

Funding

No funding or financial support was received for this study.

Availability of data and materials

The datasets generated and analyzed during the current study are not publicly available due to the original datasets containing personal privacy information but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This retrospective study was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. The requirement for informed consent was waived by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University because of the retrospective nature of the study. We confirmed that all methods were performed in accordance with the relevant guidelines and regulations (For example: Declarations of Helsinki).

Consent for publication

Not applicable.

Competing interests

The authors have declared that no conflict of interest exists.

Author details

¹Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.

²Department of Medical Ultrasound, Guangxi International Zhuang Medical Hospital, Nanning, Guangxi Zhuang Autonomous Region, China.

Received: 17 June 2022 Accepted: 16 August 2022

Published online: 22 August 2022

References

- Peres LC, Cushing-Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA, Schildkraut JM, Doherty JA. Invasive epithelial ovarian cancer survival by histotype and disease stage. *J Natl Cancer Inst*. 2019;111(1):60–8.
- Laios A, Gryparis A, DeJong D, Hutson R, Theophilou G, Leach C. Predicting complete cytoreduction for advanced ovarian cancer patients using nearest-neighbor models. *J Ovarian Res*. 2020;13(1):117.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(1):7–30.
- Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. *Am J Surg Pathol*. 2010;34(3):433–43.
- Paik ES, Lee JW, Park JY, Kim JH, Kim M, Kim TJ, Choi CH, Kim BG, Bae DS, Seo SW. Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods. *J Gynecol Oncol*. 2019;30(4):e65.
- Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, et al. Ovarian cancer, version 1.2016. NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2016;14(9):1134–63.
- Campbell S. Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening. *Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol*. 2012;40(3):245–54.
- Fehrmann RS, Li XY, van der Zee AG, de Jong S, Te Meerman GJ, de Vries EG, Crijns AP. Profiling studies in ovarian cancer: a review. *Oncologist*. 2007;12(8):960–6.
- Yoshida K, Yokoi A, Kato T, Ochiya T, Yamamoto Y. The clinical impact of intra- and extracellular miRNAs in ovarian cancer. *Cancer Sci*. 2020;111(10):3435–44.
- Biggs WS, Marks ST. Diagnosis and management of adnexal masses. *Am Fam Physician*. 2016;93(8):676–81.
- Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R, Boellard R, Dekker A, et al. Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer (Oxford, England: 1990)*. 2012;48(4):441–6.
- Bodalal Z, Trebeschi S, Nguyen-Kim TDL, Schats W, Beets-Tan R. Radiogenomics: bridging imaging and genomics. *Abdom Radiol (New York)*. 2019;44(6):1960–84.
- Aerts H. Data science in radiology: a path forward. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2018;24(3):532–4.
- Youk JH, Kwak JY, Lee E, Son EJ, Kim JA. Grayscale ultrasound radiomic features and shear-wave elastography radiomic features in benign and malignant breast masses. *Ultraschall in der Medizin (Stuttgart, Germany : 1980)*. 2020;41(4):390–6.
- Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue R, Even AJG, Jochems A, et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nat Rev Clin Oncol*. 2017;14(12):749–62.
- Saini A, Breen I, Pershad Y, Naidu S, Knuttinen MG, Alzubaidi S, Sheth R, Albadawi H, Kuo M, Oklu R. Radiogenomics and Radiomics in Liver Cancers. *Diagnostics (Basel, Switzerland)*. 2018;9(1):4.
- Yin P, Mao N, Zhao C, Wu J, Chen L, Hong N. A triple-classification radiomics model for the differentiation of primary chordoma, giant cell tumor, and metastatic tumor of sacrum based on T2-weighted and contrast-enhanced T1-weighted MRI. *J Magn Reson Imag JMRI*. 2019;49(3):752–9.
- Peng Y, Lin P, Wu L, Wan D, Zhao Y, Liang L, Ma X, Qin H, Liu Y, Li X, et al. Ultrasound-based radiomics analysis for preoperatively predicting different histopathological subtypes of primary liver cancer. *Front Oncol*. 2020;10:1646.
- Akazawa M, Hashimoto K. Artificial intelligence in gynecologic cancers: current status and future challenges—a systematic review. *Artif Intell Med*. 2021;120: 102164.
- van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RGH, Fillion-Robin JC, Pieper S, Aerts H. Computational radiomics system to decode the radiographic phenotype. *Can Res*. 2017;77(21):e104–7.
- Zwanenburg A, Vallières M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. *Radiology*. 2020;295(2):328–38.
- Qian L, Ren J, Liu A, Gao Y, Hao F, Zhao L, Wu H, Niu G. MR imaging of epithelial ovarian cancer: a combined model to predict histologic subtypes. *Eur Radiol*. 2020;30(11):5815–25.
- Zhu H, Ai Y, Zhang J, Zhang J, Jin J, Xie C, Su H, Jin X. Preoperative nomogram for differentiation of histological subtypes in ovarian cancer based on computer tomography radiomics. *Front Oncol*. 2021;11: 642892.
- Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, Cibula D, Concin N, Fischerova D, Froyman W, et al. ESGO/ISUOG/IOTA/ESGE consensus statement on preoperative diagnosis of ovarian tumors. *Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol*. 2021;58(1):148–68.
- Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, et al. European society of gynaecological oncology (ESGO) guidelines for ovarian cancer surgery. *Int J Gynecol Cancer*. 2017;27(7):1534–42.
- Froyman W, Landolfo C, De Cock B, Wynants L, Sladkevicius P, Testa AC, Van Holsbeke C, Domali E, Fruscio R, Epstein E, et al. Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. *Lancet Oncol*. 2019;20(3):448–58.

27. Avanzo M, Wei L, Stancanella J, Vallières M, Rao A, Morin O, Mattonen SA, El Naqa I. Machine and deep learning methods for radiomics. *Med Phys*. 2020;47(5):e185–202.
28. Wagner MW, Namdar K, Biswas A, Monah S, Khalvati F, Ertl-Wagner BB. Radiomics, machine learning, and artificial intelligence-what the neuroradiologist needs to know. *Neuroradiology*. 2021;63(12):1957–67.
29. Eltorai AEM, Bratt AK, Guo HH. Thoracic radiologists' versus computer scientists' perspectives on the future of artificial intelligence in radiology. *J Thorac Imag*. 2020;35(4):255–9.
30. Avanzo M, Stancanella J, Pirrone G, Sartor G. Radiomics and deep learning in lung cancer. *Strahlenther Onkol*. 2020;196(10):879–87.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

